Incidence of prostate cancer in Sicily: Results of a multicenter case-findings protocol

European Urology

Volumn 47, Issue 5, 2005, Pages 569-574

  Aragona, F ^a   Pepe, P ^a   Motta, M ^b   Saita, A ^b   Raciti, G ^c   La Rosa, P ^c   Nicolosi, D ^c   Dammino, A ^c   Minaldi, G ^b   Rizza, G ^d   Azzarello, G ^e   Aragona, C ^f   Rotondo, S ^f   Orestano, L ^g   Serrao, A ^h   Amico, F ^h   Dibenedetto, G ⁱ   Cosentino, V ^j   Iurato, C ^j   Raffino, S ^k   Gulletta, M ^l   Calarco, A ^l   Paola, Q ^m   Barbera, M ^m   Gulino, V ^h   Capizzi, G ^h   Orestano, F ^g   more..

^a CANNIZZARO HOSPITAL   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c Centro di riferimento regionale per le Malattie Neuroimmunologiche   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e General Hospital   (Italy)

^f Azienda Ospedaliera Papardo   (Italy)

^g Urology Unit   (Italy)

^h Ospedale Civile   (Italy)

ⁱ Urology Unit   (Italy)

^j Urology Unit   (Italy)

^k Outpatient Consultant   (Italy)

^l Urology Unit   (Italy)

^m Medical Oncology Unit Ospedale Civile   (Italy)

more..

Author keywords

Early diagnosis; Extended prostate biopsy; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; STATISTICAL SIGNIFICANCE;

EID: 20244366106     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.11.007     Document Type: Article

References (31)

1. J. Ferlay, F. Bray, P. Pisani, and D. Parkin GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, version 1.0. IARC Cancer Base n.5 2001 IARC Press Lyon
2. A. Quaglia, S. Parodi, P. Grosclaude, C. Martinez-Garcia, J.W. Coebergh, and M. Vercelli Differences in the epidemic rise and decrease of prostate cancer among geographical areas in Southern Europe. An analysis of differential trends in incidence and mortality in France, Italy and Spain Eur J Cancer 39 2003 654 665
3. R.E. Tarone, K.C. Chu, and O.W. Brawley Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates Epidemiology 11 2000 167 170
4. F. Meyer, L. Moore, and J. Bairati Downward trend in prostate cancer mortality in Quebec and Canada J Urol 161 1999 1189 1191
5. W. Horninger, A. Reissigl, H. Rogarsch, H. Volgger, M. Studen, and H. Klocker Prostate cancer screening in the Tyrol, Austria: experience and results Eur J Cancer 36 2000 1322 1335
6. G. Bartsch, W. Horninger, H. Klocker, A. Reissigl, W. Oberaigner, and D. Schonitzer Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria Urology 58 2001 417 424
7. G. Lu-Yao, P. Albertsen, J. Stanford, T. Stukel, E. Walker-Corkery, and M. Barry Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut BMJ 325 2002 740
8. V. Ravery, L. Goldblatt, B. Royer, E. Blanc, M. Tonblanc, and L. Boccon-Gibod Extensive biopsy protocol improves the detection rate of protocol cancer J Urol 164 2000 393 396
9. F. Boccardo, S. Ciatto, and G. Martorana Italian National Consensus Conference on Prostate Cancer Screening. Final Consensus Document Int J Biol Markers 18 2003 238 240
10. D. Ransohoff, M. McNaughton, M. Collins, and F. Fowler Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback Am J Med 113 2002 663 667
11. A. Russo, M. Autelitano, A. Bellini, and L. Bisanti Estimate of population coverage with the PSA test to screen for prostate cancer in a metropolitan area of northern Italy J Med Screen 9 2002 179 180
12. L. Holmberg, A. Bill-Axelson, F. Helgesen, J.O. Salo, P. Folmez, and M. Haggman A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer N Engl J Med 347 2002 781 789
13. F. Labrie, B. Candas, L. Cusan, J.L. Gomez, A. Belanger, and G. Brousseau Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial Prostate 59 2004 311 318
14. J. Hugosson, G. Aus, H. Lilja, P. Lodding, and C.G. Pihl Results of a randomized, population-based study of biennial screening using serum PSA measurement to detect prostate cancer Cancer 100 2004 1397 1405
15. W. Horninger, A. Berger, A. Pelzer, H. Klocker, W. Oberaigner, and D. Schonitzer Screening for prostate cancer: update experience from the Tyrol study Curr Urol Rep 5 2004 220 225
16. P. Gann, C. Hennekens, and M. Stampfer A prospective evaluation of plasma PSA for detection of prostatic cancer JAMA 273 1995 289 294
17. L.H. Kuller, A. Thomas, G. Grandits, and J.D. Neaton Elevated PSA levels up to 25 years prior to death from prostate cancer Cancer Epidemiol Biomarkers Prev 13 2004 373 377
18. W. Catalona, D. Smith, and D. Ornstein Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements JAMA 277 1997 1452 1455
19. D. Smith, G. Carvalhal, and D. Mager Use of lower PSA cutoffs for prostate cancer screening in black and white men J Urol 160 1998 1734 1738
20. R. Babaian, D. Johnston, and W. Naccarato The incidence of prostate cancer in a screening population with a serum PSA between 2.5 and 4.0 ng/mL: relation to biopsy strategy J Urol 165 2001 757 760
21. I. Thompson, D. Pauler, P. Goodman, C. Tangen, M. Lucia, and H. Parnes Prevalence of prostate cancer among men with a PSA level ≤ 4.0 ng per milliliter N Engl J Med 350 2004 2239 2246
22. T. Kobayashi, K. Nishizawa, K. Ogura, K. Mitsumori, and Y. Ide Detection of prostate cancer in men with PSA levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population Urology 63 2004 727 731
23. F. Schroder, I. van der Cruijssen-Koeter, H. de Koning, A.N. Vis, R.F. Hoedemaeker, and R. Kranse Prostate cancer detection at low PSA J Urol 163 2000 806 812
24. J. Gomez de Vicente, M. Lujan Galan, A. Paez Borda, A. Romero Cagigal, A. Moreno Santurino, and D. Santos Arrontes Detecciòn del cancer de prostata en el rango del PSA entre 3 y 3,9 ng/ml Actas Urol Esp 26 2002 272 274
25. W. Horninger, A. Berger, H. Rogatsch, A. Gschwendtner, H. Steiner, and M. Niescher Characteristics of prostate cancers detected at low PSA levels Prostate 58 2004 232 237
26. M. Sokoloff, X. Yang, M. Fumo, D. Mhoon, and C. Brendler Characterizing prostatic adenocarcinomas in men with a serum PSA level of <4 ng/mL BJU Int 93 2004 499 502
27. W. Horninger, H. Volgger, H. Rogatsch, A. Gschwendtner, and G. Bartsch Consideration of low PSA cut-off levels to optimize the detection of curable prostate cancer Eur Urol 39 Suppl 4 2001 43 46
28. J. Krumholz, G. Carvalhal, C. Ramos, D. Smith, P. Thorson, and Y. Yan PSA cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features Urology 60 2002 469 473
29. R. Punglia, A. D'Amico, W. Catalona, K. Roehl, and K. Kuntz Effect of verification bias on screening for prostate cancer by measurement of PSA N Engl J Med 349 2003 335 342
30. P. Labrie, B. Candas, L. Cusan, J. Gomez, A. Belanger, and G. Brousseau Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial Prostate 59 2004 311 318
31. H. Ballantine Carter Prostate cancers in men with low PSA levels: must we find them? N Engl J Med 350 2004 22 23